| Aspect | Key points | Evidence & notes (paper, year) | Citation ID |
|---|---|---|---|
| Identity / exon structure / imprinting | UniProt O95467 corresponds to NESP55, a distinct protein product of the human GNAS locus rather than Gsα. It is produced from its own upstream promoter/first exon and is maternally expressed because the NESP promoter/DMR is methylated on the paternal allele. | Explicitly identified as “NESP55 (UniProt ID: O95467)” and described as transcriptionally/structurally distinct from Gsα; multiple GNAS reviews and primary studies state NESP55 is a separate imprinted GNAS product with maternal expression (Fonin et al., 2019; Iwasaki et al., 2023; Yang et al., 2023; Cipriano et al., 2024). | (pqac-00000001, pqac-00000002, pqac-00000003, pqac-00000004) |
| Identity / exon structure / imprinting | The GNAS locus is complex and produces multiple products (Gsα, XLαs, A/B, antisense transcripts, NESP55). NESP55 should not be conflated with canonical Gsα signaling protein products. | Recent reviews and mechanistic studies emphasize distinct promoters/first exons and different imprinting patterns across GNAS products; Figure 1A in Iwasaki et al. schematizes NESP55 separately from Gsα and other transcripts (Iwasaki et al., 2023). | (pqac-00000000, pqac-00000002, pqac-00000003, pqac-00000010) |
| Biochemical nature & processing | NESP55 is a chromogranin-like/neuroendocrine secretory precursor rather than an enzyme or transporter. It undergoes post-translational processing to smaller peptides. | Review summarizing foundational cloning/biochemistry describes NESP55 as a “novel chromogranin-like precursor” that is post-translationally processed into peptides; one processed peptide was reported to have 5-HT1B antagonist activity (Bastepe, 2007, citing earlier primary work). | (pqac-00000008) |
| Biochemical nature & processing | NESP55 is highly intrinsically disordered relative to Gsα isoforms, consistent with granin/secretory precursor behavior. | Structure-function review reports NESP55 has high predicted disorder (~86.5% PDR) and no sequence similarity to other GNAS isoforms, reinforcing that it is biochemically distinct from G protein α-subunits (Fonin et al., 2019). | (pqac-00000001) |
| Localization | NESP55 localizes to neuroendocrine secretory compartments and is associated with chromogranin-like granules/regulated secretion rather than plasma membrane signal transduction. | Bastepe review summarizes localization studies showing preferential localization in adrenaline-synthesizing cells of bovine and rat adrenal medulla, consistent with secretory granules and a neuroendocrine secretory role (Bastepe, 2007). | (pqac-00000008) |
| Expression / tissues | NESP55 is a neuroendocrine-enriched product; reported in adrenal medulla/chromaffin cells and other neuroendocrine tissues/tumors. | Review and biomarker literature note presence in chromaffin cells, pituitary, pheochromocytoma tissue, neuroblastomas, insulinomas, and other pancreatic neuroendocrine tumors; older tissue-distribution work in bovine tissues is summarized by Bastepe (2007), and Yukina et al. (2024) reiterate neuroendocrine distribution. | (pqac-00000008, pqac-00000011) |
| Physiology / functional inference | NESP55 is not assigned a canonical catalytic reaction; current understanding supports a role as a regulated secretory-granule precursor within neuroendocrine cells. | The available evidence supports precursor/secretory function and peptide generation, while recent GNAS-locus papers focus mainly on imprinting control rather than direct molecular mechanism of NESP55 action (Bastepe, 2007; Iwasaki et al., 2023; Li et al., 2024). | (pqac-00000008, pqac-00000002, pqac-00000005) |
| Disease / clinical relevance | NESP55 transcript regulation matters clinically through GNAS imprinting disorders: reduced NESP expression and altered antisense transcription are implicated in pseudohypoparathyroidism type 1B with broad GNAS methylation defects. | Li et al. (2024) identified recurrent small variants in the NESP55/NESPAS region in affected families and observed increased antisense transcripts with decreased NESP expression in patient cells, linking NESP55-region disruption to PHP1B pathogenesis. | (pqac-00000005) |
| Disease / clinical relevance | NESP55 has been explored as a neuroendocrine tumor marker, but evidence is mixed and context-dependent. | Yukina et al. (2024) note a prior study reporting NESP55 immunoreactivity in 90.9% of pancreatic neuroendocrine tumors, but in their own insulinoma cohort NESP55 was not supported as a promising tissue/circulating marker. | (pqac-00000011, pqac-00000012) |
| Disease / clinical relevance | In a 2024 insulinoma study, NESP55 did not show convincing value for association with insulin-producing tumors or aggressiveness. | Cohort size was 41 patients, with extended IHC in 10; marker levels before surgery and 2–12 months after surgery did not change significantly overall, and NESP55 was among markers not supported for further study in insulinoma (Yukina et al., 2024). | (pqac-00000012) |
| Recent 2023–2024 developments | Major recent advances concern the regulatory biology of the NESP55 region within GNAS imprinting rather than new protein-level biochemistry. | Iwasaki et al. (2023) showed the STX16-ICR acts as a long-range enhancer of maternal NESP55 transcription and that the NESP-ICR is required for A/B methylation/silencing; Li et al. (2024) connected recurrent NESP55/NESPAS-region variants to broad GNAS methylation defects in PHP1B. | (pqac-00000002, pqac-00000005) |


*Table: This table summarizes evidence-backed functional annotation for human NESP55 (GNAS; UniProt O95467), including identity, processing, localization, expression, and clinical relevance. It emphasizes what is directly supported by the retrieved literature, especially 2023-2024 studies on GNAS imprinting and biomarker use.*